A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy.

Trial Profile

A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 06 Dec 2013 According to the ClinicalTrials.gov record, Status changed from active, no longer recruiting to completed.
    • 31 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT00975715).
    • 24 Apr 2012 Planned end date changed from 1 Jan 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov (Parent trial: NCT00975715).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top